Jithin Joseph

2 papers in the library · publishing 2026

Papers

Sort Most recent Most cited

Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis.

Journal of Affective Disorders October 12, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled...

DOI: 10.1016/j.jad.2026.122619 Full text Ketamine Treatment-resistant depression Augmentation strategies Randomized controlled trials

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

DOI: 10.1016/j.jad.2026.121230 Full text Anxiety Treatment-resistant depression Iv ketamine Real-world evidence +1